TY - JOUR
T1 - An open-label trial of memantine for cognitive impairment in patients with posttraumatic stress disorder
AU - Ramaswamy, Sriram
AU - Madabushi, Jayakrishna
AU - Hunziker, John
AU - Bhatia, Subhash C.
AU - Petty, Frederick
N1 - Publisher Copyright:
© 2015 Sriram Ramaswamy et al.
PY - 2015
Y1 - 2015
N2 - Background. Studies using standard neuropsychological instruments have demonstrated memory deficits in patients with PTSD. We evaluated the efficacy and safety of the N-methyl-D-aspartate antagonist memantine in veterans with PTSD and cognitive impairment. Methods. Twenty-six veterans with PTSD and cognitive impairment received 16 weeks of memantine in an open-label fashion. Cognition was assessed using the Spatial Span, Logical Memory I, and Letter-Number Sequencing subtests of the Wechsler Memory Scale III and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). RBANS measures attention, language, visuospatial skills, and immediate and delayed memories. The Clinician Administered PTSD Scale (CAPS), Hamilton Depression Scale (HAM-D), Hamilton Anxiety Scale (HAM-A), Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), and Sheehan Disability Scale (SDS) were secondary outcome measures. Results. There was a significant improvement in RBANS, both total and subscale scores (P
AB - Background. Studies using standard neuropsychological instruments have demonstrated memory deficits in patients with PTSD. We evaluated the efficacy and safety of the N-methyl-D-aspartate antagonist memantine in veterans with PTSD and cognitive impairment. Methods. Twenty-six veterans with PTSD and cognitive impairment received 16 weeks of memantine in an open-label fashion. Cognition was assessed using the Spatial Span, Logical Memory I, and Letter-Number Sequencing subtests of the Wechsler Memory Scale III and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). RBANS measures attention, language, visuospatial skills, and immediate and delayed memories. The Clinician Administered PTSD Scale (CAPS), Hamilton Depression Scale (HAM-D), Hamilton Anxiety Scale (HAM-A), Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), and Sheehan Disability Scale (SDS) were secondary outcome measures. Results. There was a significant improvement in RBANS, both total and subscale scores (P
UR - http://www.scopus.com/inward/record.url?scp=84930629871&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84930629871&partnerID=8YFLogxK
U2 - 10.1155/2015/934162
DO - 10.1155/2015/934162
M3 - Article
AN - SCOPUS:84930629871
VL - 2015
JO - Journal of Aging Research
JF - Journal of Aging Research
SN - 2090-2204
M1 - 934162
ER -